Raji-Null Cells
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Raji-Null Cells Human lymphoblast cells - ADCC CD19/CD20/Control Target Cells |
Show product |
3-7 x 10e6 cells |
raji-null
|
|
Control Human B-cell line
Examples of applications using the Raji-null cell line
Raji-Null cells were developed from the human Raji cell line. Raji-Null cells constitutively express different antigens at their cell surface that can be targeted by specific antibodies, notably to induce antibody-dependent cellular cytotoxicity (ADCC).
-Human CD20 is highly expressed by Raji cells. It has no known natural ligand and is thought to act as calcium channel enabling optimal B-cell responses [1]. Human CD20 is a clinically-relevant target in mAb-mediated therapy (rituximab, ofatumumab, obinutuzumab) for non-Hodgkin's B cell lymphoma or chronic lymphocytic leukemia [2].
-Human CD19 is highly expressed by Raji cells. It acts as a co-receptor decreasing the threshold for antigen B-cell receptor (BCR)-dependent stimulation [1]. Human CD19 is a clinical target for anti-hCD19-CD3 bis-specific antibodies (blinatumomab) in non Hodgkin's B cell lymphoma [3].
- Human PD-L1 (programmed cell death ligand 1; also known as CD274 or B7-H1) is expressed at low levels by Raji cells. This transmembrane protein is expressed by hematopoietic and nonhematopoietic cells and is induced by pro-inflammatory cytokines, such as in the tumor microenvironment [4]. Human PD-L1 is a clinically-relevant target in mAb-mediated therapy (atezolizumab, durvalumab, avelumab) for a wide range of cancers [4].
Features of Raji-Null cells:
- Constitutive expression of CD19 and CD20 at the cell surface
- Constitutive low expression of PD-L1 at the cell surface
- Stable expression of a resistance gene to Blasticidin
Applications for Raji-Null cells:
- ADCC target cells using anti-hCD19, anti-hCD20, anti-hPD-L1 Abs
- Negative control target cells in ADCC assays using monoclonal Abs other than anti-hCD19, anti-hCD20, anti-hPD-L1 Abs
- Target cells for anti-hCD19-CD3 bispecific Abs
Validation of Raji-Null cells:
- Functionally tested as target cells in ADCC assays using anti-human CD20 monoclonal Abs and Jurkat-Lucia™ NFAT-CD16 cells
- Functionally tested as negative control target cells in ADCC assays using monoclonal Abs other than anti-hCD20 (e.g. anti-hCTLA-4 or anti-hPD-1 Abs)
- Functionally tested as target cells in T-cell activation assay using anti-hCD19-CD3 bi-specific Ab and Jurkat-Lucia™ NFAT cells.
References:
1. Bae J. et al. 2005. Identification of CD19 and CD20 peptides for the induction of antigen-specific CTLs against B-cell malignancies. Clin. Cancer. Res. 11:1629-38.
2. Almagro J.C. et al. 2018. Progress and challenges in the development of antibodies for cancer therapy. Front. Immunol. 8:1751.
3. Bargou R. et al. 2008. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 321(5891):974-7.
4. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
Specifications
Quality control:
- Human CD20 expression has been verified by flow-cytometry.
- Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using InvivoGen’s anti-hCD20-hIgG1 antibody and Jurkat-NFAT Lucia™ CD16 reporter cell line.
- The stability for 20 passages following thawing has been verified.
- Raji-Null cells are guaranteed mycoplasma-free.
Contents
- 1 vial of Raji-Null cells (3-7 x 106 cells) in Freezing Medium
- 1 ml of Blasticidin (10 mg/ml). Store at 4 °C or at -20 °C.
- 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria and fungi. Store at -20 °C.
IMPORTANT: Cells are shipped frozen. If cells are not frozen upon arrival, contact InvivoGen immediately.
Shipped on dry ice (Europe, USA & Canada)
Back to the top